Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epigenomics AGFRA:ECX 20 3-Year EBITDA Growth Rate is 69.40% as of Dec. 2025, which is 509% above its 10-year median of 11.40. GuruFocus rates FRA:ECX with a GF Score™ of 20/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 164 Medical Diagnostics & Research companies, Epigenomics AG ranks better than 95.73% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 69.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 54.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 41.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Epigenomics AG was 69.40% per year. The lowest was -63.50% per year. And the median was 11.40% per year.
Epigenomics AG (FRA:ECX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Epigenomics AG 3-Year EBITDA Growth Rate Related Terms
FRA:ECX vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Epigenomics AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's 3-Year EBITDA Growth Rate falls into.
Epigenomics AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 69.40% mean?
Epigenomics AG (FRA:ECX) has a 3-Year EBITDA Growth Rate of 69.40% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Epigenomics AG and its competitors. This is 509% above median its historical median of 11.40. According to the industry distribution chart, Epigenomics AG ranks #7 out of 164 companies in the Medical Diagnostics & Research industry, placing it in the top 4.3%.
Is Epigenomics AG's 3-Year EBITDA Growth Rate too high?
Epigenomics AG's current 3-Year EBITDA Growth Rate of 69.40% is 509% above median its 10-year median of 11.40. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.30. Epigenomics AG's value of 69.40% is 514.2% above this industry median. Based on the distribution chart, Epigenomics AG ranks #7 out of 164 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Epigenomics AG has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #7 out of 164 companies for 3-Year EBITDA Growth Rate. This places Epigenomics AG in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.30. Epigenomics AG's value of 69.40% is 514.2% above this benchmark. While the company's 10-year median is 11.40 vs. the industry median of 11.30, Epigenomics AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.30, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epigenomics AG's current 3-Year EBITDA Growth Rate of 69.40% is 514.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current 3-Year EBITDA Growth Rate is 69.40%, which is 509% above median its own 10-year median of 11.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.91 — trading 911.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 69.40%, which is 509% above median its 10-year median of 11.40 and 514.2% above the Medical Diagnostics & Research industry median of 11.30. Epigenomics AG's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current 3-Year EBITDA Growth Rate is 69.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.91 is trading 911.1% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
3-Year EBITDA Growth Rate: 69.40% (509% above median its 10-year median of 11.40)
GF Value™: €0.09 vs. price of €0.91 (911.1% above fair value)
Industry Position: 514.2% above the Medical Diagnostics & Research median (#7 of 164)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
20GF Score
Get the complete analysis for FRA:ECX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
